背景与目的达芬奇机器人手术系统在胸外科的应用日益广泛,本研究旨在探讨经达芬奇机器人手术治疗I期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的疗效。方法回顾2012年1月-2017年12月于我科行手术治疗的Ⅰ期NSCLC患者347例,...背景与目的达芬奇机器人手术系统在胸外科的应用日益广泛,本研究旨在探讨经达芬奇机器人手术治疗I期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的疗效。方法回顾2012年1月-2017年12月于我科行手术治疗的Ⅰ期NSCLC患者347例,依据手术方式分为机器人(robot-assisted thoracic surgery, RATS)组134例及腔镜(videoassisted thoracic surgery, VATS)组213例。比较两组患者围术期一般指标(术中出血量、术后引流量、术后带管时间、术后住院时间、淋巴结清扫状况),分析患者生存状况(overall survival, OS)、无进展生存状况(disease free survival, DFS)及相关影响因子。结果机器人组与腔镜组术中出血量[(49±39) mL vs (202±239) mL]、术后引流量[Day 1:(248±123)mL vs (350±213) mL; Day 2:(288±189) mL vs (338±189) mL]比较,机器人组均少于腔镜组(P<0.05);术后带管时间[(10±5) d vs (11±8) d]及住院时间[(13±6) d vs (14±9) d]两组患者无明显差异(P>0.05)。机器人组与腔镜组的淋巴结清扫组数[(5±2)组vs (4±2)组]及淋巴清扫数量[(18±9)枚vs(11±8)枚]比较,机器人组均优于腔镜组(P<0.05)。机器人组与腔镜组生存状况比较[1年生存率:97.3%vs 96%、3年生存率:89.8%vs 83.1%、5年生存率:87.5%vs 70.3%,平均生存时间(month):61 vs 59],两组无统计学差异(P>0.05)。无进展生存状况:机器人组与腔镜组比较[1年无进展生存率:93.7%vs 91.3%、3年无进展生存率:87.7%vs 68.4%、5年无进展生存率:87.7%vs 52.5%,平均无进展生存时间(month):61 vs 50],机器人组明显优于腔镜组(P<0.05)。单因素分析显示,淋巴结清扫数量是患者生存状况的影响因子;肿瘤直径、手术方式、淋巴结清扫组数、淋巴结清扫数量为患者无进展生存状况的影响因子。多因素分析显示生存状况无独立影响因子,肿瘤直径及手术方式为无进展生存状况的独立影响因子。结论达芬奇机器人Ⅰ期非小细胞肺癌患者术后生展开更多
AIM To investigate the relationship between hypoxia-inducible factor-1α(HIF-1α), prolyl 4-hydroxylase beta(P4 HB) expression, and clinicopathologic parameters, as well as the prognostic value of these genes for pati...AIM To investigate the relationship between hypoxia-inducible factor-1α(HIF-1α), prolyl 4-hydroxylase beta(P4 HB) expression, and clinicopathologic parameters, as well as the prognostic value of these genes for patients with gastric cancer(Gc).METHODS Hypoxia is a critical factor that shapes the Gc microenvironment. In previous reports, we have demonstrated that P4 HB is a potential target of HIF-1α. In the present study, gene expression profiling interactive analysis(GEPIA) was used to analyze the relationship between P4 HB and hypoxia-associated genes. To this end, 428 Gc tissue samples were used to analyze the expression of HIF-1α and P4 HB via immunohistochemical staining. Patient samples were classified as having weak-expression or over-expression both in terms of HIF-1α and P4 HB. Correlations between biomarkers and clinicopathological factors were analyzed to predict survival. RESULTS P4 HB demonstrated a positive correlation with hypoxiaassociated genes(P < 0.05). HIF-1α and P4 HB overexpression have a significant correlation with TNM staging(χ2 = 23.32, P = 0.00; χ2 = 65.64, P = 0.00) and peritoneum cavity metastasis(χ2 = 12.67, P = 0.00; χ2 = 39.29, P = 0.00). In univariate analysis, patients with a high HIF-1α expression trend had a shorter disease-free survival(DFS: 44.80 mo vs 22.06 mo) and overall survival(OS: 49.58 mo vs 39.92 mo). P4 HB overexpression reflected similar results: patients with over-expression of P4 HB had a shorter survival time than those with weak-expression(DFS: 48.03 mo vs 29.64 mo, OS: 52.48 mo vs 36.87 mo). Furthermore, HIF-1α is also a clinicopathological predictor of dismal prognosis according to multivariate analysis(DFS, 95%c I: 0.52-0.88, P < 0.00; OS, 95%c I: 0.50-0.85, P < 0.00). However, P4 HB was meaningful in DFS(95%c I: 0.58-1.00, P < 0.05) but not in OS(95%c I: 0.72-1.23, P > 0.05).CONCLUSION Overexpression of HIF-1α and P4 HB is associated with poor prognosis in patients with Gc. Thus, these genes may be potential prognostic biomarker candidates in GC展开更多
目的:探讨血小板与淋巴细胞比值(platelet to lymphocyte ratio,PLR)对三阴性乳腺癌的临床预后影响及与免疫球蛋白表达的关系。方法:回顾性分析2006年1月至2012年12月于我院乳腺外科住院治疗的134例三阴性乳腺癌患者。临床独立预后因素...目的:探讨血小板与淋巴细胞比值(platelet to lymphocyte ratio,PLR)对三阴性乳腺癌的临床预后影响及与免疫球蛋白表达的关系。方法:回顾性分析2006年1月至2012年12月于我院乳腺外科住院治疗的134例三阴性乳腺癌患者。临床独立预后因素采用单因素和多因素Cox回归模型分析。术后生存时间和生存曲线比较采用Kaplan-Meier和log-rank方法。结果:PLR是三阴性乳腺癌的独立预后因素,最佳临界值为155.00。PLR<155.00组,术后中位DFS为35.51月,中位OS为55.24月;PLR≥155.00组,术后中位DFS为25.07月,中位OS为35.17月。两组术后DFS和OS比较,差异具有统计学意义(P<0.05)。结论:PLR是三阴性乳腺癌的独立预后因素,具有重复性强、非侵袭性、方便实用等特性,可用于预测三阴性乳腺癌临床预后。展开更多
文摘背景与目的达芬奇机器人手术系统在胸外科的应用日益广泛,本研究旨在探讨经达芬奇机器人手术治疗I期非小细胞肺癌(non-small cell lung cancer, NSCLC)患者的疗效。方法回顾2012年1月-2017年12月于我科行手术治疗的Ⅰ期NSCLC患者347例,依据手术方式分为机器人(robot-assisted thoracic surgery, RATS)组134例及腔镜(videoassisted thoracic surgery, VATS)组213例。比较两组患者围术期一般指标(术中出血量、术后引流量、术后带管时间、术后住院时间、淋巴结清扫状况),分析患者生存状况(overall survival, OS)、无进展生存状况(disease free survival, DFS)及相关影响因子。结果机器人组与腔镜组术中出血量[(49±39) mL vs (202±239) mL]、术后引流量[Day 1:(248±123)mL vs (350±213) mL; Day 2:(288±189) mL vs (338±189) mL]比较,机器人组均少于腔镜组(P<0.05);术后带管时间[(10±5) d vs (11±8) d]及住院时间[(13±6) d vs (14±9) d]两组患者无明显差异(P>0.05)。机器人组与腔镜组的淋巴结清扫组数[(5±2)组vs (4±2)组]及淋巴清扫数量[(18±9)枚vs(11±8)枚]比较,机器人组均优于腔镜组(P<0.05)。机器人组与腔镜组生存状况比较[1年生存率:97.3%vs 96%、3年生存率:89.8%vs 83.1%、5年生存率:87.5%vs 70.3%,平均生存时间(month):61 vs 59],两组无统计学差异(P>0.05)。无进展生存状况:机器人组与腔镜组比较[1年无进展生存率:93.7%vs 91.3%、3年无进展生存率:87.7%vs 68.4%、5年无进展生存率:87.7%vs 52.5%,平均无进展生存时间(month):61 vs 50],机器人组明显优于腔镜组(P<0.05)。单因素分析显示,淋巴结清扫数量是患者生存状况的影响因子;肿瘤直径、手术方式、淋巴结清扫组数、淋巴结清扫数量为患者无进展生存状况的影响因子。多因素分析显示生存状况无独立影响因子,肿瘤直径及手术方式为无进展生存状况的独立影响因子。结论达芬奇机器人Ⅰ期非小细胞肺癌患者术后生
基金Supported by Liaoning S and T Project,No.2015020269Doctor fund of Liaoning Province Cancer Hospital and Institute,No.Z1410
文摘AIM To investigate the relationship between hypoxia-inducible factor-1α(HIF-1α), prolyl 4-hydroxylase beta(P4 HB) expression, and clinicopathologic parameters, as well as the prognostic value of these genes for patients with gastric cancer(Gc).METHODS Hypoxia is a critical factor that shapes the Gc microenvironment. In previous reports, we have demonstrated that P4 HB is a potential target of HIF-1α. In the present study, gene expression profiling interactive analysis(GEPIA) was used to analyze the relationship between P4 HB and hypoxia-associated genes. To this end, 428 Gc tissue samples were used to analyze the expression of HIF-1α and P4 HB via immunohistochemical staining. Patient samples were classified as having weak-expression or over-expression both in terms of HIF-1α and P4 HB. Correlations between biomarkers and clinicopathological factors were analyzed to predict survival. RESULTS P4 HB demonstrated a positive correlation with hypoxiaassociated genes(P < 0.05). HIF-1α and P4 HB overexpression have a significant correlation with TNM staging(χ2 = 23.32, P = 0.00; χ2 = 65.64, P = 0.00) and peritoneum cavity metastasis(χ2 = 12.67, P = 0.00; χ2 = 39.29, P = 0.00). In univariate analysis, patients with a high HIF-1α expression trend had a shorter disease-free survival(DFS: 44.80 mo vs 22.06 mo) and overall survival(OS: 49.58 mo vs 39.92 mo). P4 HB overexpression reflected similar results: patients with over-expression of P4 HB had a shorter survival time than those with weak-expression(DFS: 48.03 mo vs 29.64 mo, OS: 52.48 mo vs 36.87 mo). Furthermore, HIF-1α is also a clinicopathological predictor of dismal prognosis according to multivariate analysis(DFS, 95%c I: 0.52-0.88, P < 0.00; OS, 95%c I: 0.50-0.85, P < 0.00). However, P4 HB was meaningful in DFS(95%c I: 0.58-1.00, P < 0.05) but not in OS(95%c I: 0.72-1.23, P > 0.05).CONCLUSION Overexpression of HIF-1α and P4 HB is associated with poor prognosis in patients with Gc. Thus, these genes may be potential prognostic biomarker candidates in GC
文摘目的:探讨血小板与淋巴细胞比值(platelet to lymphocyte ratio,PLR)对三阴性乳腺癌的临床预后影响及与免疫球蛋白表达的关系。方法:回顾性分析2006年1月至2012年12月于我院乳腺外科住院治疗的134例三阴性乳腺癌患者。临床独立预后因素采用单因素和多因素Cox回归模型分析。术后生存时间和生存曲线比较采用Kaplan-Meier和log-rank方法。结果:PLR是三阴性乳腺癌的独立预后因素,最佳临界值为155.00。PLR<155.00组,术后中位DFS为35.51月,中位OS为55.24月;PLR≥155.00组,术后中位DFS为25.07月,中位OS为35.17月。两组术后DFS和OS比较,差异具有统计学意义(P<0.05)。结论:PLR是三阴性乳腺癌的独立预后因素,具有重复性强、非侵袭性、方便实用等特性,可用于预测三阴性乳腺癌临床预后。
